Imiquimod

• Background:

  Imiquimod activates the toll-like receptor7 /8 to secrete cytokines (primarily interferon-α (IFN-α), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)). It also has been shown to act as an adoside A1 and A2A receptor antagonist. It is clinically useful in the treatment of superficial basal cell carcinoma.

• Description:

  TLR7/8 Agonist

• Product Name Alternative:

  1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; R837; S26308; TMX-101

• UNSPSC:

  41116105

• Type:

  Agonist

• Source:

  Synthetic

• Field of Research:

  Immunology | Innate Immunity | TLR Signaling | Neuroscience | Neurodegeneration | Alzheimer's Disease | Cell Signaling | Protein Phosphorylation | Serine / Threonine Kinases

• Purity:

  >98% (HPLC) ; NMR: (Conforms)

• Weight:

  0.005

• Format:

  White powder

• Solubility:

  May be dissolved in DMSO (2 mg/ml, warm)

• Molecular Formula:

  C14H16N4

• Molecular Weight:

  240.3

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Kan Y., et al. (2012) J Virol. 86(19): 10338-10346.

• CAS Number:

  99011-02-6